Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5019719 | 0.92 | MAPT (0.33) | MAPTPTPN11KMT2APOLBCYP3A4 | |
| SCHEMBL4561040 | 0.90 | KMT2A (0.35) | MAPTPTPN11KMT2ANR3C1TDP1 | |
| SCHEMBL986998 | 0.87 | STIM1 (0.42) | PTPN11KMT2ANR3C1L3MBTL1 | |
| SCHEMBL15356925 | 0.86 | CYP11B2 (0.31) | — | |
| SCHEMBL1781817 | 0.84 | KMT2A (0.50) | MAPTKMT2APOLBTDP1CHRNA7 | |
| SCHEMBL5019710 | 0.84 | MAPT (0.34) | MAPTPTPN11KMT2APOLBCYP3A4 | |
| SCHEMBL5019765 | 0.83 | CSNK1D (0.37) | MAPTPTPN11TDP1L3MBTL1 | |
| SCHEMBL5019638 | 0.82 | KMT2A (0.41) | MAPTKMT2APOLBTDP1CHRNA7 | |
| SCHEMBL5019609 | 0.82 | AVPR2 (0.42) | MAPTKMT2APOLBTDP1CHRNA7 | |
| SCHEMBL5019637 | 0.82 | KMT2A (0.41) | MAPTKMT2ANR3C1POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289071-A1 | TETRAZOLYL-TETRAHYDROPYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2012064808-A1 | TETRAZOLYL - TETRAHYDROPYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE - RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289071-A1 | TETRAZOLYL-TETRAHYDROPYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | TSLP, IL5, TPMT | MAPT 497/4885PTPN11 1503/4885KMT2A 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.